Life Expectancy and Management in Polycythemia Vera

Survival Data by Age and Historical Context

In contemporary cohorts, the overall median survival of patients with polycythemia vera (PV) approaches or exceeds 20 years, with reported ranges from 14.1 to 27.6 years. 2
Younger adults diagnosed with PV (≤ 40 years) have a markedly longer median survival, estimated at 24–37 years. 3
Prior to modern therapy, untreated or inadequately treated PV was associated with a median survival of only 2–4 years. 5

Maintaining hematocrit below 45 % through aggressive phlebotomy improves median survival to greater than 10 years, compared with less than 4 years when hematocrit control is inadequate. 5
Low‑dose aspirin therapy reduces the incidence of cardiovascular death, myocardial infarction, stroke, and venous thromboembolism in PV patients. 7
Risk‑stratified cytoreductive therapy—administered to high‑risk patients (age > 60 years or prior thrombotic event)—further enhances survival outcomes. 7
Avoiding leukemogenic agents such as chlorambucil in favor of safer cytoreductive options lowers the risk of therapy‑related leukemia and contributes to longer survival. 5

The European LeukemiaNet guidelines clarify that the median survival estimate of > 10 years applies to primary myelofibrosis, not to PV, underscoring the distinct, more favorable prognosis of PV. 2
Clinical practice should emphasize early patient education about the favorable long‑term prognosis of PV once the diagnosis is confirmed. 2
Optimal management includes strict hematocrit control, routine low‑dose aspirin (unless contraindicated), and initiation of cytoreductive therapy for high‑risk disease to sustain the improved survival advantage. 7